During the first four months of 2018, the imports of finished medicinal products to Russia amounted to 156.1 billion rubles (in prices set for release for free circulation). Over the same period, the supplies of in-bulk products reached 35.9 billion rubles.
This was a modest 0.9% increase in ruble terms compared to the similar period of 2017. At the same time, the supplies of in-bulk products increased by 27.7% year-on-year. Total amount of medicines imported to Russia since the beginning of 2018 increased by 5.0% in ruble terms.
In Q1 2018, physical supplies of finished drugs amounted to 575.2 million packages, which is 7.9% less than in 2017. April results were even worse, with a 15% drop compared to the same period of 2017. This is the lowest volume in the past 1.5 years. Overall, in April 2018, Russia imported 131.6 million packages of finished drugs.
In physical terms, the most significant decline in supplies of finished drugs for Q1 2018 was reported for such companies as Recordati Group (-69%), Danapha Pharmaceutical (-61%), and AGIO (-49%). Over the year, Recordati Group, a French company, reduced the list of imported drugs by 7 items. Moreover, the imports fell for 7 out of 10 remaining items. This trend has particularly affected such drugs as Hexaspray, Otofa, and Izofra.
This year, Danapha pharmaceutical, a company known for such products as Little Star and Golden Star, supplied only the latter and, in addition, these supplies fell 58% year-on-year. The imports by AGIO are falling mostly as a result of reduced range of imported drugs, in particular Prednisone. For other medicines, the dynamics are relatively good.